Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
ADNOC Gas Targets Up to $4B Profit in 2026 
Gold Prices Hold Near Seven-Week High as Markets Await U.S. Inflation Data 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
US Yen Intervention Unlikely to Deliver Lasting Recovery, Yardeni Says 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
US Judge Dismisses Gautam Adani Criminal Charges 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
US Tightens Ebola Controls as Congo Outbreak Sparks Global Concern 
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
GSK Reportedly Nears $9 Billion Acquisition of Cancer Drug Developer Nuvalent 
South Korean pharmaceutical and biotech companies are collaborating to develop new drugs using artificial intelligence (AI).
AI can predict whether a chemical compound is suitable for human use, thereby speeding up the identification of potential substances and enabling the selection of appropriate clinical patients.
There are over 100 cases where candidate substances for new drugs are under development using AI, with over 50 percent carried out through collaborations between domestic and foreign companies, according to the Korea Pharmaceutical and Bio-pharma Manufacturers Association.
HK inno.N Corp. and AinB recently signed an MOU to identify a new antibody candidate substance for cell and gene therapies and establish an antigen design platform for vaccine development.
Last year, Pharos iBio inked a deal with Yuhan Corp. to promote the joint study and technology transfer of the AI-based KRAS inhibitor.
This company is now carrying out a phase 1 clinical trial in Korea and Australia after developing PHI-101, a candidate substance for the treatment of leukemia, using its AI platform, Chemiverse.
Moreover, Oncocross, which has AI technology to identify the optimal disease for drugs, signed a joint study and development contract with Boryung Corp. in February to expand the indications of hypertension treatment.
